english.prescrire.org > Prescrire International > N°183 - June 2017

n°183

June 2017

Issue Contents
Editorial

Free  Compensate victims!

p.143

Marketing Authorisations

Tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (Genvoya°) and HIV

p.145-146
Another formulation of tenofovir, with no proven advantages

Osimertinib (Tagrisso°) in T790M mutation-positive lung cancer

p.147-148
Preliminary evaluation

Aprepitant (Emend°) in children

p.149-151
Manage drug interactions on a case-by-case basis

Inset. Aprepitant interactions

p.150

INN Common stem: -pitant

p.151

Adverse Effects

Palmar-plantar erythrodysesthesia with anti-VEGF cancer drugs

p.152-153

Drugs for multiple sclerosis and progressive multifocal leukoencephalopathy

p.153

Nasopharyngeal decongestants: atrial fibrillation

p.154

Apremilast (Otezla° tablets): watch out for suicidal ideation

p.154

Strontium withdrawn, at last

p.154

Reviews

Hypertension and diabetes

p.155-160
If chlortalidone is unavailable, an ACE inhibitor is the first choice

Prescrire's proposals. Treatment of hypertension in adults with diabetes (outside of pregnancy)

p.159

Outlook

Free  Drug packaging in 2016: marketing takes precedence over public health

p.161-165

Free  Facts and Figures

p.166-167
The finances of Association Mieux Prescrire: 2016 Prescrire annual report

Masthead

Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe